Hereditary Breast Cancer: When Family History Means Something More
Roughly 85-90% of breast cancer isn't hereditary — it happens without an identifiable inherited gene mutation. But the remaining 10-15% is, and if that's you or your family, the risk numbers, screening recommendations, and even prevention options look meaningfully different than the general population's. The goal here isn't to make you anxious about a family history you already knew about — it's to help you recognize when that history is worth a specific referral, not just something to mention in passing at your annual visit.
Last updated August 2026
The genes involved — it's not just BRCA
BRCA1 and BRCA2 are the best known, and carry the highest, most well-characterized risk, but current genetic testing standard of care uses multi-gene panels rather than testing BRCA alone — panels also check genes like PALB2, TP53, PTEN, CHEK2, and ATM, each with its own risk profile and associated cancer types. This matters practically: a negative BRCA-only test years ago doesn't mean you've been fully evaluated by today's standards.
What the actual risk numbers look like
The general population's lifetime breast cancer risk is about 13%. A BRCA1 mutation raises that to roughly 55-72%; BRCA2 to roughly 45-69% — both are substantial, not marginal, increases. BRCA1 carriers also face a notably elevated ovarian cancer risk and a higher likelihood of triple-negative breast cancer specifically (a subtype with fewer targeted treatment options); BRCA2 carriers face elevated risks too, plus increased risk of male breast cancer, prostate cancer, and pancreatic cancer in the family — which is part of why family history from both sides, and both male and female relatives, matters.
When genetic counseling is worth pursuing
Specific patterns in your personal or family history point toward a hereditary component worth formally evaluating: breast cancer diagnosed before age 50 (in you or a relative), triple-negative breast cancer at any age, breast cancer in multiple close relatives, any ovarian cancer in the family, male breast cancer in the family, pancreatic cancer in the family alongside breast or ovarian cancer, or Ashkenazi Jewish ancestry (where the BRCA carrier rate is roughly 1 in 40, versus roughly 1 in 400-500 in the general population). Any one of these alone is worth raising with your provider — you don't need all of them.
What testing actually involves
Genetic counseling before testing — not just the test itself — is the standard of care. A genetic counselor helps map your actual family history, decides which panel makes sense for your situation, and helps you understand what different possible results (positive, negative, or a "variant of uncertain significance," a change in the gene whose effect on risk isn't yet clear) would actually mean before you're facing that result in real time. The test itself is simple — a blood or saliva sample.
If you test positive
Enhanced surveillance (earlier and more frequent mammograms, often alongside breast MRI, starting well before the general population's screening age) is the starting point. Risk-reducing surgery — prophylactic mastectomy, and prophylactic removal of the ovaries and fallopian tubes (which also substantially reduces ovarian cancer risk and is often recommended once childbearing is complete, typically around age 35-40 for BRCA1 given its earlier ovarian cancer onset) — are real options many carriers consider, not just a last resort. Chemoprevention medications (tamoxifen or raloxifene) are another option for reducing risk without surgery. And because each first-degree relative of a carrier has roughly a 50% chance of carrying the same mutation, cascade testing — offering testing to parents, siblings, and children — is a standard next step, not an overreaction.
If you test negative
A negative result on a known family mutation is genuinely reassuring. But a negative panel test in the absence of a known family mutation doesn't fully rule out elevated risk if your family history is still strong — in that situation, your risk may still be estimated using family-history-based risk models rather than genetics alone, and enhanced surveillance may still be appropriate. This is a nuance worth discussing directly with your provider or genetic counselor rather than assuming "negative" always means "back to average risk."
Worth discussing with your provider
Educational information only — general patterns that vary by person. This is not medical advice, a diagnosis, or a substitute for care from your own clinician.
More from Education